A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Abroad (travel likely)RecruitingPHASE3

Conditions

Non-small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Contact: Principal Investigator (Yilong Wu)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Abroad (travel likely)Recruiting

Kunming, China

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Non-small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2, PHASE3

Birmingham, United States · Anchorage, United States

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE3

Lund, Sweden

A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

Non-small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE3

Shanghai, China